New pill shows promise for leukemia patients out of options
NCT ID NCT04872478
First seen Jan 11, 2026 · Last updated May 04, 2026 · Updated 13 times
Summary
This early-stage trial tests an experimental pill called MRX-2843 in teens and adults whose acute leukemia has returned or not responded to standard treatments. The main goal is to check the drug's safety and find the best dose. About 50 participants will take the pill daily in 28-day cycles.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Emory University - WINSHIP Cancer Center
RECRUITINGAtlanta, Georgia, 30322, United States
Contact
-
Emory University, Children's Healthcare of Atlanta
RECRUITINGAtlanta, Georgia, 30322, United States
Contact
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
Contact
Contact
Conditions
Explore the condition pages connected to this study.